New study aims to unravel Parkinson's protein mysteries

NCT ID NCT07474779

Not yet recruiting Knowledge-focused Sponsor: University of Pavia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how abnormal proteins, like alpha-synuclein and tau, build up and affect brain function in people with Parkinson's disease. Researchers will use brain scans, blood tests, and skin biopsies to track these changes. The goal is to find better ways to diagnose and understand the disease, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could identify new biomarkers and improve understanding of how Parkinson's disease progresses, potentially guiding future treatments.
What could go wrong: This is an early-stage observational study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GBA1 PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GBA1 PARKINSON DISEASE PARKINSON'S DISEASE (PD) REM SLEEP BEHAVIOR DISORDER (IRBD)

New study aims to unravel Parkinson's protein mysteries

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions